The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences

Figures & data

Table 1 Summary of JUPITER and AURORA trial results

Endpoint	Rosuvastatin rates per 100 person-year	Placebo rates per 100 person-year	Relative risk reduction %	P value
JUPITER results	N = 8901	N = 8901
Primary endpoint	0.77	1.36	44	<0.00001
Nonfatal MI	0.12	0.33	65	<0.00001
Nonfatal stroke	0.16	0.31	48	0.003
Arterial revasc	0.38	0.71	46	<0.0001
MI, stroke, and CV death	0.45	0.85	47	<0.00001
Death from any cause	1	1.25	20	0.02
AURORA results	N = 1389	N = 1384
Primary endpoint	9.2	9.5	4	0.59
Nonfatal MI	2.1	2.5	16	0.23
Nonfatal stroke	1.2	1.1	NA	0.42
Death from CV cause	7.2	7.3	0	0.97
Death from any cause	13.5	14	4	0.51
Death from non-CV causes	5.5	6	8	0.34

Abbreviations: MI, myocardial infarction; revasc, revascularizations; CV, cardiovascular.